Patent Commercialization

Product Commercialization

• The most common path — using patents defensively to protect a product business
• Patents deter competitors from copying
• The direct commercial value comes from the product, not the patent itself
• But patents block competitors from copying key features, which has indirect commercial value

Licensing (Voluntary)

• Patents are licensed to third parties who pay royalties to practice the invention
• The patent owner retains ownership
• Licensee pays for the right to make/use/sell products covered by the patent
• Licensing can be exclusive (one licensee) or non-exclusive (multiple licensees)

Patent Assertion/enforcement

• Identifying companies that infringe the patent (without a license) and demanding payment
• Enforcement can be through: cease-and-desist letters
• Negotiated settlements
• District court litigation
• ITC Section 337 proceedings

Portfolio Sale

• Selling the patent portfolio outright to another company
• Common when: the company changes strategic direction
• The portfolio is not core to the business
• The company needs capital
• The buyer is typically: a competitor
• A patent assertion entity (PAE)
• A portfolio aggregator (IV, Acacia, etc.)

Cross-licensing

• Exchanging licenses with another company
• No cash changes hands
• Each party licenses the other's portfolio
• Common between: large technology companies (smartphones, semiconductors)
• Companies with blocking patents against each other

Standards Essential Patents (SEP) Licensing

• Patents declared essential to a technical standard (Wi-Fi, 4G/5G, HEVC) must be licensed on FRAND (fair, reasonable, and non-discriminatory) terms
• SEP owners collect royalties from all implementers of the standard
• Highly valuable but subject to regulatory and legal scrutiny (Qualcomm, InterDigital, etc.)

Donation/dedication

• Donating patents to a patent pool (e.g., LOT Network, Open Invention Network)
• Provides defensive value without licensing revenue
• Can be used for tax deductions if donated to a nonprofit.

Step 1 — Portfolio Assessment

• Not all patents are worth licensing
• Assess each patent for: claim scope (broader → more licensing leverage)
• Strength (prior art risk; prosecution history problems)
• Coverage of commercial products/processes in the market
• Expiration date (patents expiring soon have less value)

Infringement Analysis

• Who is practicing the invention (without a license)?
• Compare claim charts to public information about competitor products
• Reverse engineering reports
• Technical publications

Market Scan

• Identify all companies in the relevant market
• Assess which companies are making, using, selling, or importing products that practice the claims

Prioritization

• Large companies first (larger royalty base)
• Companies with clear infringement (strongest claims)
• Companies in growing markets (longer royalty stream)

Comparable Royalty Rates

• What do licenses in this technology area typically charge?
• Georgia-Pacific factors (15-factor test for reasonable royalty from patent infringement damages)
• LUMP SUM vs.

Running Royalty

• Lump sum = one-time payment
• Clean
• Preferred by some licensees
• Running royalty = percentage of revenue on covered products
• Preferred by patent owners for growing products

Typical Rates

• Software patents: 0.5-3% of product revenue
• Pharmaceutical: 2-10% of net sales
• Hardware: 0.25-2%

Step 4 — Licensing Outreach

• Initial outreach: often a letter identifying the patent and suggesting a meeting
• NOT a C&D letter initially (starts negotiation)

Negotiations

• Claim charts showing specific product coverage
• Royalty proposal
• FRAND offer if relevant

Step 5 — Licensing Agreement

• Exclusivity (exclusive → higher rate; more restrictions; non-exclusive → lower rate; multiple licensees)
• Field of use restrictions
• Geographic scope
• Term
• Sublicensing rights
• Audit rights
• Most favored nation (MFN) clause.

Step 1 — Identify Infringement

• Claims analysis against the accused product/process
• Prepare claim charts mapping every claim element to specific features of the accused product
• Typically requires both legal and technical analysis

Step 2 — Pre-suit Investigation

• Seagate/Halo considerations: does the defendant know about the patent?
• Marking requirements (35 U.S.C. § 287): if products covered by the patent have not been properly marked (patent number on product or patent.com website virtual marking), damages may be limited to period after actual notice

Cease-and-desist Letter

• Identifies the patent
• Identifies the accused products
• Demands that infringement cease and/or the defendant take a license
• This provides 'actual notice' for damages purposes
• Triggers Halo willfulness consideration (defendant now knows about the patent)
• 21-day 'safe harbor' under Rule 11 starts running

Settlement Discussion

• Many infringement disputes are resolved by license without litigation
• Typically 60-80% of patent assertions settle before trial

US District Court

• Must be filed in a proper venue (28 U.S.C. § 1400(b))
• After TC Heartland (S.Ct. 2017): venue limited to defendant's state of incorporation OR where defendant has regular/established place of business and has infringed
• Western District of Texas (Waco)
• District of Delaware
• Northern District of California are popular venues

ITC (International Trade Commission)

• Section 337 investigation for imported products
• Very fast (12-18 months to a final determination)
• Remedy = exclusion order (blocks importation)
• Useful for products manufactured abroad

Step 5 — Litigation

• Claim construction
• Fact discovery
• Expert reports
• Summary judgment
• Trial

Injunction

• Enjoin continued infringement
• eBay Inc. v. MercExchange (S.Ct. 2006): four-factor test
• Practicing patent owners more likely to get injunctions than NPEs

Damages

• At least a reasonable royalty
• Can include lost profits
• Willful infringement → enhanced damages up to 3×.

Bayh-dole Act (1980)

• Allows universities and small businesses that receive federal research funding to own and commercialize patents resulting from that research
• Prior to Bayh-Dole, the government owned patents resulting from federally-funded research
• Bayh-Dole transformed academic IP
• Created the modern university tech transfer office (TTO) model
• TECHNOLOGY TRANSFER OFFICES (TTOs): most research universities have dedicated TTOs
• Key TTO functions: invention disclosure review (researchers disclose inventions to TTO)
• Patent filing decisions (TTO decides whether to file patents on disclosed inventions)
• Licensing and commercialization (TTO markets inventions to industry)
• Startup formation support (assist faculty/staff in forming spinout companies)
• Royalty distribution (TTO manages royalties and distributes share to inventors)

Exclusive Licensing

• Grants an exclusive license to one company (often a startup)
• Company agrees to milestones and minimum royalties
• University retains rights for non-commercial research use
• Most common for early-stage technologies requiring significant development investment

Non-exclusive Licensing

• Multiple companies can license
• Lower royalty rates
• Common for more mature, broadly applicable technologies

Start-up Formation

• Many university inventions are commercialized through spinouts formed by faculty/grad students
• TTO provides: exclusive license to the startup
• Business formation support
• Investor introductions

Royalty Distribution

• Typical university royalty distribution: 35-50% to inventor(s)
• 20-30% to the inventor's department
• 20-30% to the central university (TTO)
• Some universities have formulas that shift more to inventors at high royalty levels

Successful Examples

• Lyrica (Northwestern): $750M+ royalties
• CRISPR-Cas9 (UC Berkeley/Broad Institute): billions in licensing
• Gatorade (University of Florida): ~$150M+
• Google PageRank (Stanford): ~$336M licensing.

Definition

• A PAE (also called a 'non-practicing entity' or 'NPE', and colloquially a 'patent troll' when used pejoratively) acquires patents and generates revenue through licensing or litigation
• Key distinction: the PAE does not manufacture products that practice the patents

Acquisition-based Pae

• Buys patents from operating companies, universities, or inventors
• Asserts the acquired patents against manufacturers/service providers in the relevant industry
• Typical PAE acquisition terms: upfront payment + share of licensing revenues
• Operating companies often sell to PAEs when the patents no longer align with their core business

Aggregation-based Pae

• IV (Intellectual Ventures): largest patent aggregator
• Holds 70,000+ patents
• Generates licensing revenue from the portfolio

Assertion-focused Pae

• Acacia Research, WSOU Investments: specialize in aggressive patent assertion
• Large litigation dockets

Target Selection

• PAEs typically target: large revenue companies (larger royalty base)
• Companies that cannot afford prolonged litigation
• Companies that would rather settle than disclose product internals

Small Company Targets

• 'shakedown' letters to small companies
• Settlement amounts ($5,000-$50,000) often less than cost of defending

Legal Framework

• PAEs have all the same legal rights as operating company patent owners
• eBay v. MercExchange (S.Ct. 2006): NPEs generally cannot get injunctions (they can only get monetary damages)
• This limits PAE leverage compared to operating companies
• TC Heartland (2017): limited venue shopping — reduced ability to file in plaintiff-friendly venues

Defensive Strategies

• Against PAE assertion: challenge patent validity via IPR
• Find prior art through crowd-sourcing (Ask Patents, Article One Partners)
• Join LOT Network (licenses flow to members when PAEs acquire the patents)
• FRAND challenge if standards-essential claims.